Pemphigus FoliaceusSymptoms, Doctors, Treatments, Advances & More
Pemphigus Foliaceus Overview
Learn About Pemphigus Foliaceus
- Pemphigus foliaceus
- PF
UCI Health Dermatology Center
Sergei Grando is a Dermatologist practicing medicine in Irvine, California. Dr. Grando is rated as an Elite provider by MediFind in the treatment of Pemphigus Foliaceus. He is also highly rated in 11 other conditions, according to our data. His clinical expertise encompasses Pemphigus Vulgaris, Pemphigus, Pemphigus Foliaceus, and Bullous Pemphigoid. Dr. Grando is board certified in American Board Of Dermatology - Dermatology. Dr. Grando is currently accepting new patients.
Emory Clinic At 1525 Clifton Road
Ron Feldman is a Dermatologist practicing medicine in Atlanta, Georgia. Dr. Feldman is rated as an Elite provider by MediFind in the treatment of Pemphigus Foliaceus. He is also highly rated in 10 other conditions, according to our data. His clinical expertise encompasses Bullous Pemphigoid, Pemphigus Foliaceus, Pemphigus, and Pemphigus Vulgaris. Dr. Feldman is board certified in American Board Of Dermatology, 2010. Dr. Feldman is currently accepting new patients.
Urgent Care Century City
Michael Kasperkiewicz is a Dermatologist practicing medicine in Los Angeles, California. Dr. Kasperkiewicz is rated as an Elite provider by MediFind in the treatment of Pemphigus Foliaceus. He is also highly rated in 9 other conditions, according to our data. His clinical expertise encompasses Pemphigus, Pemphigus Vulgaris, Bullous Pemphigoid, and Pemphigus Foliaceus. Dr. Kasperkiewicz is currently accepting new patients.
Summary: This is an investigator-initiated, single-center, single-arm, open-label exploratory clinical study designed to evaluate the safety, tolerability, and preliminary efficacy of autologous CD19 CAR-T cell therapy in patients with refractory pemphigus vulgaris.
Summary: Pemphigus vulgaris (PV) is a chronic, potentially life-threatening autoimmune mucocutaneous disorder that significantly impairs patients' quality of life. While systemic corticosteroids and immunosuppressants remain the standard of care, many patients suffer from persistent, painful oral lesions that exhibit delayed healing or poor response to conventional systemic protocols. This clinical trial i...
Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center

